Click Here to return To Results

 

A Controlled Study of Intravenous Immunoglobulin in Demyelinating Neuropathy with IgM Gammopathy Ann Neurol 40:792-795, Dalakas,M.C.,et al, 1996 See this aricle in Pubmed Article Abstract Eleven patients with demyelinating polyneuropathy associated with monoclonal IgM antibodies were randomized to receive IVIg or placebo monthly for three months in a double-blind study.After a washout period, they crossed over to the alternate therapy.Response was gauged by evaluating muscle strength,sensation and neuromuscular symptoms at baseline after three months and at treatment's end.After IVIg therapy,the strength improved in only 2 of 11 patients by 28 and 38.5 points from baseline and declined after placebo.In 1 other patient,the sensory score improved by 13 points.Antibody titers to MAG/SGPD or gangliosides did not appreciably change.We conclude that IVIg has only a modest benefit to not more than 18%of patients with IgM paraproteinemic demyelinating neuropathy.

Related Tags

(click to filter results - removes previous filter) gammaglobulin therapy,intravenous monoclonal gammopathy neuropathy neuropathy,peripheral,treatment paraproteinemia polyneuropathy treatment of neurologic disorder

Click Here to return To Results